SecBot SecBot
6-K ·Filed Aug 3, 2026

RDY

DR REDDYS LABORATORIES LTD
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001575872-26-000547
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor the launch timeline and initial prescription uptake through Fresenius Kabi; the U.S. rituximab market is large but competitive, so early partner execution will determine revenue contribution. Watch for subsequent 6-K filings with commercial updates or guidance.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

RDY drug pipeline →

rituximab

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and launched in the US (FDA approval ~August 2026). Now in commercial phase, with Fresenius Kabi handling US commercialization.
Next catalyst
None dated

What to watchThe FDA approval is already priced in and was announced approximately 3.5 weeks ago. Watch for initial sales data from Fresenius Kabi's US commercialization and Dr. Reddy's quarterly earnings for any biosimilar revenue disclosures. For a diversified pharma company of RDY's size ($10.3B market cap), this single biosimilar is unlikely to be a major share-price mover. The more relevant catalysts would be broader pipeline updates, resolution of the Form 483 at Bachupally, and overall generics/biosimilars segment performance.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.07
T+0 close · Aug 3, 2026 · via day close
Latest settled
+13.92%
T+60 · $13.75
Vs SPY
+12.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $12.07entry
  2. T+1 · 4mo ago +0.25%α −1.55% · $12.10
  3. T+5 · 3mo ago +0.66%α −1.36% · $12.15
  4. T+20 · 3mo ago +0.50%α −0.74% · $12.13
  5. T+60 · 21d ago +13.92%α +12.34% · $13.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's announced U.S. FDA approval of its rituximab biosimilar (biosimilar to Rituxan) on the goal date, strengthening its global biosimilars portfolio. Fresenius Kabi will exclusively commercialize the product in the U.S. market, expanding Dr. Reddy's footprint in the world's largest pharmaceutical market. No financial terms were disclosed.

Key Facts

  • U.S. FDA approved Dr. Reddy's rituximab biosimilar on the agency's goal date, following a successful pre-license inspection at its biologics facility in Bachupally, Hyderabad.
  • Fresenius Kabi holds exclusive rights to commercialize the product in the United States.
  • The rituximab biosimilar is already commercialized in India, the European Union, the UK, and more than 25 emerging markets, with additional approvals in Switzerland and Canada.
  • The approval is supported by analytical, non-clinical and clinical evidence demonstrating high similarity to the reference product with no clinically meaningful differences in safety, purity, or potency.

Financial Impact

New U.S. market entry for rituximab biosimilar; no financial terms or revenue guidance disclosed in the filing.

revenuemarket share

Risk Factors

  • Competitive pressure from existing rituximab biosimilars (e.g., from Celltrion, Pfizer, Sandoz) could limit market share and pricing power.
  • Commercialization depends entirely on Fresenius Kabi's sales execution and distribution network.
  • Post-approval manufacturing or supply chain issues could delay launch or restrict supply.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000547
Document: 0001575872-26-000547-index.html0001575872-26-000547
Document: 0001575872-26-000547.txt0001575872-26-000547

Track record

73 reports on RDY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026